Endometriosis affects around 1 in 10 women of reproductive age in the UK, yet the average time to diagnosis is more than 9 ...

People with polyendocrine metabolic ovarian syndrome (PMOS) should have their condition diagnosed sooner and be offered an annual review to monitor symptoms, treatment and long-term health risks, ...

It’s the first time a NICE committee has reviewed the evidence behind the procedure which preserves the donor liver by pumping oxygenated blood through it using a machine for around two hours. This ...

There is a simple discount patient access scheme for pirtobrutinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Adults with acute ST-segment-elevation myocardial infarction (STEMI) who present within 12 hours of onset of symptoms have primary percutaneous coronary intervention (PCI), as the preferred coronary ...

Decisions about updating our guidance are made by NICE’s prioritisation board. For more information on the principles and process, see NICE-wide topic prioritisation: the manual. For information about ...

Evidence-based recommendations on trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments in adults. Next review: More ...

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

intermittently scanned continuous glucose monitoring. HCL systems are only recommended if they are procured at a cost-effective price agreed by the companies and NHS England, and implemented following ...

Evidence-based recommendations on amivantamab (Rybrevant) with carboplatin and pemetrexed for untreated advanced non-small-cell lung cancer with activating EGFR exon 20 insertion mutations in adults.

Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch ...

This guideline covers safe and effective use of medicines in health and social care for people taking 1 or more medicines. It aims to ensure that medicines provide the greatest possible benefit to ...